A Few Signs That Martin Shkreli Might Be In Some Trouble | Lowering the Bar


Although his smirk has not yet wavered.

Source: A Few Signs That Martin Shkreli Might Be In Some Trouble | Lowering the Bar

Shkreli smirks through eighth “not guilty” as lawyer successfully delays trial | Ars Technica


Unbothered by new criminal charge, the former CEO periscopes his way out of court.

Source: Shkreli smirks through eighth “not guilty” as lawyer successfully delays trial | Ars Technica

“A good day for Martin Shkreli,” who may try to pin fraud on former counsel | Ars Technica


Feds mulling additional charges as CEO’s former company, Turing, gets sued.

Source: “A good day for Martin Shkreli,” who may try to pin fraud on former counsel | Ars Technica

In comeback bid, Shkreli’s old company gets OK to buy life-saving drug | Ars Technica


Amid outcry, KaloBios may jack the drug’s price and make millions off FDA voucher.

Source: In comeback bid, Shkreli’s old company gets OK to buy life-saving drug | Ars Technica

Greed, lies, and Shkreli’s smug “performance”: Lawmakers go ballistic


Hearing exposes Turing’s lavish spending, while exec says they’re losing money.

Source: Greed, lies, and Shkreli’s smug “performance”: Lawmakers go ballistic

Martin Shkreli’s other pharma company files for bankruptcy | Ars Technica


After firing indicted CEO, company now fights to keep shares listed on NASDAQ.

Source: Martin Shkreli’s other pharma company files for bankruptcy | Ars Technica

Martin Shkreli’s other pharma company is dramatically collapsing | Ars Technica


Following arrest of CEO, KaloBios loses CFO, accountants, is delisted from Nasdaq.

Source: Martin Shkreli’s other pharma company is dramatically collapsing | Ars Technica

Turing’s reviled Shkreli indicted for securities fraud over “Ponzi-like” scheme [Updated] | Ars Technica


$750/pill CEO accused of illegally using assets from former company to pay debts.

Source: Turing’s reviled Shkreli indicted for securities fraud over “Ponzi-like” scheme [Updated] | Ars Technica

Turing’s Martin Shkreli regrets 5,000% price hike—says it wasn’t high enough | Ars Technica


In a Healthcare summit hosted by Forbes on Thursday, Martin Shkreli, the founder and CEO of Turing Pharmaceuticals, admitted he made a mistake by raising the price of a decades-old drug by more than 5,000 percent. But it’s not the mistake you might expect.

Source: Turing’s Martin Shkreli regrets 5,000% price hike—says it wasn’t high enough | Ars Technica

$750/pill pharma company reverses decision to lower drug price | Ars Technica

Turing will offer hospitals and patients discounts, but high list price stands.

Source: $750/pill pharma company reverses decision to lower drug price | Ars Technica